Medical management of malignant bowel obstruction in patients with advanced cancer: 2021 MASCC guideline update
ConclusionThe panel recommends octreotide in non-operable MBO. Randomized trials are needed to clarify ranitidine and antiemetic choices.
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Colon Cancer | Colorectal Cancer | Gastroenterology | Metoclopramide | Ranitidine | Study | Zyprexa